SG Americas Securities LLC lifted its stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 701.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 162,514 shares of the company's stock after acquiring an additional 142,245 shares during the period. SG Americas Securities LLC owned approximately 0.35% of Urogen Pharma worth $1,797,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in URGN. KLP Kapitalforvaltning AS acquired a new stake in Urogen Pharma in the 4th quarter valued at approximately $59,000. Lazard Asset Management LLC acquired a new position in Urogen Pharma during the 4th quarter worth approximately $67,000. GAMMA Investing LLC grew its stake in shares of Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after acquiring an additional 7,392 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Urogen Pharma in the fourth quarter valued at approximately $101,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Urogen Pharma in the fourth quarter worth $126,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Urogen Pharma
In other news, insider Mark Schoenberg sold 5,162 shares of Urogen Pharma stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the transaction, the insider now directly owns 153,378 shares in the company, valued at approximately $1,130,395.86. The trade was a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 5.10% of the company's stock.
Urogen Pharma Stock Performance
URGN stock traded up $1.63 during trading hours on Thursday, reaching $14.87. The stock had a trading volume of 3,965,606 shares, compared to its average volume of 1,030,493. The stock has a 50-day simple moving average of $8.79 and a 200 day simple moving average of $10.10. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $18.15. The stock has a market capitalization of $685.66 million, a PE ratio of -4.68 and a beta of 0.40. The company has a debt-to-equity ratio of 4.77, a current ratio of 5.65 and a quick ratio of 5.47.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. The firm had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. Analysts predict that Urogen Pharma will post -3.12 EPS for the current fiscal year.
Analyst Ratings Changes
Several research analysts recently commented on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Urogen Pharma in a report on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price for the company. Guggenheim restated a "buy" rating and set a $30.00 price objective (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. The Goldman Sachs Group set a $16.00 target price on Urogen Pharma and gave the company a "neutral" rating in a research report on Friday, June 13th. Finally, D. Boral Capital reissued a "buy" rating and set a $25.00 price target on shares of Urogen Pharma in a research report on Thursday, June 12th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $32.86.
Read Our Latest Analysis on Urogen Pharma
Urogen Pharma Profile
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Recommended Stories
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
